Search results for "DISEASES"

showing 10 items of 20537 documents

Potential benefits of colostrum in gastrointestinal diseases

2016

This paper reviews the composition of colostrum and the potential preventive and therapeutic use of this "first milk" for treating various gastrointestinal disorders in humans. Colostrum is a complex biological liquid that is richer in antimicrobial peptides, immune-regulating compounds and growth factors than the subsequent mature milk. The main functions of colostrum are to provide essential nutritional components, strengthen the natural defense system, modulate immune response, balance intestinal microbiota and enhance the growth and repair of several tissues. Several studies and clinical trials carried out both in vitro and in vivo on humans and animals suggest the clinical benefits of …

0301 basic medicineGastrointestinal Diseasesanimal diseasesAntimicrobial peptidesPhysiologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesImmune systemfluids and secretionsImmunityIn vivogastrointestinal diseases dysbiosis colostrumMedicineAnimalsHumansClinical significanceColostrum Anti-Microbical Factors Immunity Growth Factors Intestinal Disorders ReviewGeneral Immunology and Microbiologybusiness.industryColostrumfood and beveragesmedicine.diseaseClinical trial030104 developmental biologyDietary SupplementsColostrumCattleFemalebusinessDysbiosis
researchProduct

Retrospective Serological Evidence of High Exposure of Globally Relevant Zoonotic Parasite Toxoplasma Gondii in The Latvian Population

2019

Abstract Toxoplasmosis is an important infection caused by the single-celled parasite Toxoplasma gondii, which is a zoonotic parasite causing widespread human and animal diseases, mostly involving the central nervous system. Humans can acquire toxoplasmosis by ingestion of raw or undercooked meat containing T. gondii tissue cysts, ingestion of oocysts shed by infected felids via contaminated food or water, and by vertical transmission to the fetus through the placenta from the mother during pregnancy. The aim of the present study was to determine the seroprevalence of specific anti-T. gondii IgG and IgM antibodies using a large set of clinical diagnostic laboratory data obtained over a 14-y…

0301 basic medicineGeneral interestScience030231 tropical medicinePopulationSerological evidence03 medical and health sciences0302 clinical medicineparasitic diseasesParasite hostingeducationeducation.field_of_studyMultidisciplinaryseroprevalencebiologyQToxoplasma gondiiLatvian030108 mycology & parasitologybiology.organism_classificationVirologylanguage.human_languagecomorbidityagelarge scalelanguagepregnancytoxoplasmosisProceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
researchProduct

Cirrhosis risk score of the donor organ predicts early fibrosis progression after liver transplantation.

2019

Background & Aims: Fibrosis progression (FP) after liver transplantation (LT) increases morbidity and mortality. Biomarkers are needed for early prediction of FP. A recipient’s seven-gene cirrhosis risk score (CRS) has been associated with FP, especially in non-transplant cohorts. A broader validation of CRS, including the genotype of the donor-organ and HCV-negative patients is lacking. We therefore analyzed the impact of donor- and recipient-specific genotypes on FP after LT in a large cohort of HCV-positive and -negative patients.Method: Genotyping from liver biopsies (n=201 donors) and peripheral blood (n=442 recipients) was performed. Cirrhosis risk score was correlated with FP at …

0301 basic medicineGenetic MarkersLiver CirrhosisMalemedicine.medical_specialtyCirrhosisTime Factorsmedicine.medical_treatmentLiver transplantationGastroenterologyRisk Assessment03 medical and health sciences0302 clinical medicineFibrosisRisk FactorsInternal medicineGenotypeotorhinolaryngologic diseasesMedicineHumansCumulative incidenceGenetic Predisposition to DiseaseFramingham Risk Scorebusiness.industryHazard ratioGastroenterologyMiddle Agedmedicine.diseaseTissue DonorsLiver Transplantation030104 developmental biologyPhenotypeTreatment OutcomeDisease Progression030211 gastroenterology & hepatologyFemalebusinessRisk assessmentJournal of gastrointestinal and liver diseases : JGLD
researchProduct

Aedes albopictus diversity and relationships in south-western Europe and Brazil by rDNA/mtDNA and phenotypic analyses: ITS-2, a useful marker for spr…

2021

AbstractBackgroundAedes albopictusis a very invasive mosquito, which has recently colonized tropical and temperate regions worldwide. Of concern is its role in the spread of emerging or re-emerging mosquito-borne diseases.Ae. albopictusfrom south-western Europe and Brazil were studied to infer genetic and phenetic diversity at intra-individual, intra-population and inter-population levels, and to analyse its spread.MethodsGenotyping was made by rDNA 5.8S-ITS-2 and mtDNAcox1 sequencing to assess haplotype and nucleotide diversity, genetic distances and phylogenetic networks. Male and female phenotyping included combined landmark-and outlined-based geometric morphometrics of wing size and sha…

0301 basic medicineGenetic MarkersMaleEntomologyAedes albopictus030231 tropical medicineZoologyInfectious and parasitic diseasesRC109-216Mosquito VectorsBiologymtDNA cox1DNA MitochondrialDNA RibosomalMolecular haplotypingNucleotide diversity03 medical and health sciences0302 clinical medicineAedesAnimalsWings AnimalSequencingGenetic variabilityDisease vectorGenotypingPhylogenyMorphometricsPhylogenetic treeResearchHaplotypeGenetic Variationbiology.organism_classificationAedes albopictusrDNA 5.8S-ITS-2Europe030104 developmental biologyInfectious DiseasesPhenotypeHaplotypesParasitologyDNA IntergenicFemaleWing geometric morphometryBrazilCloningSouth-western Europe
researchProduct

Comparison of CRISPR and Marker-Based Methods for the Engineering of Phage T7

2020

This article belongs to the Section Bacterial Viruses.

0301 basic medicineGenetic Markersviruses030106 microbiologyMutantlcsh:QR1-502t7Computational biologyGenome ViralBiologyGenomeArticlelcsh:MicrobiologyBacteriophage03 medical and health sciencesbacteriophageVirologyBacteriophage T7CRISPRClustered Regularly Interspaced Short Palindromic RepeatsGenomescrisprBacteriophageGeneSelection (genetic algorithm)Gene EditingQHT7Viral Tail Proteinsbiology.organism_classificationBacteriòfags3. Good healthQRtail fibres030104 developmental biologyInfectious DiseasesLytic cycleCRISPRMutationTail fibresCRISPR-Cas SystemsHomologous recombinationGenèticaViruses
researchProduct

Genetics and Gene Therapy of Anderson-Fabry Disease.

2018

Fabry's disease is a genetic disorder of X-linked inheritance caused by mutations in the alpha galactosidase A gene resulting in deficiency of this lysosomal enzyme. The progressive accumulation of glycosphingolipids, caused by the inadequate enzymatic activity, is responsible of organ dysfunction and thus of clinical manifestations. In the presence of a high clinical suspicion, a careful physical examination and specific laboratory tests are required, finally diagnosis of Fabry's disease is confirmed by the demonstration of absence or reduced alpha-galactosidase A enzyme activity in hemizygous men and gene typing in heterozygous females; in fact the performance of enzymatic activity assay …

0301 basic medicineGenetic enhancementChaperone therapyDisease030204 cardiovascular system & hematologyBioinformaticsMice0302 clinical medicineAlpha galactosidase ADrug DiscoveryGenetics (clinical)KidneybiologyTrihexosylceramidesGenetic disorderEnzyme replacement therapyDependovirusRecombinant ProteinsAlpha galactosidase A; Chaperone therapy; Enzyme replacement therapy; Fabry disease; Gene therapy; Viral vectors; Molecular Medicine; Molecular Biology; Genetics; Drug Discovery3003 Pharmaceutical Science; Genetics (clinical)Isoenzymesmedicine.anatomical_structureMolecular Medicinemedicine.symptomGenetic Vectors03 medical and health sciencesGene therapyViral vectorRare DiseasesGeneticGeneticsmedicineAnimalsHumansEnzyme Replacement TherapyMolecular BiologyAlpha-galactosidasebusiness.industryDrug Discovery3003 Pharmaceutical ScienceOrgan dysfunctionGenetic Therapymedicine.diseaseFabry diseaseDisease Models Animal030104 developmental biologyalpha-GalactosidaseMutationbiology.proteinFabry DiseasebusinessBiomarkersCurrent gene therapy
researchProduct

Treatment strategies for lysosomal storage disorders.

2017

Over the past several years the number of treatments available for patients with lysosomal storage disorders has rapidly increased. Haematopoietic stem cell transplantation, enzyme replacement therapy, substrate reduction, and chaperone therapies are currently available, and gene therapies and other treatments are rapidly advancing. Despite remarkable advances, the efficacy of most of these therapies is limited, particularly because the treatments are usually initiated when organ damage has already occurred. To circumvent this limitation, screening in newborn infants for lysosomal storage disorders has been introduced in many countries. However, this screening is complicated by the broad cl…

0301 basic medicineGenetic enhancementLysosomal storage disordersBioinformatics03 medical and health sciences0302 clinical medicineDevelopmental NeuroscienceSlow progressionMedicineHumansEnzyme Replacement Therapybusiness.industryHematopoietic Stem Cell TransplantationEnzyme replacement therapyGenetic TherapyOrgan damageTransplantationLysosomal Storage Diseases030104 developmental biologyPediatrics Perinatology and Child HealthImmunologyTreatment strategyNeurology (clinical)Stem cellbusiness030217 neurology & neurosurgeryMolecular ChaperonesDevelopmental medicine and child neurology
researchProduct

Atypical 1,4-dihydropyridine derivatives, an approach to neuroprotection and memory enhancement

2016

This mini review is devoted to the design and pharmacological studies of novel atypical 1,4-dihydropyridine (DHP) derivatives which differ to a great extent from the traditional DHPs either by lack of neuronal calcium channel blocking activity and/or inability to protect mitochondrial processes. About 100 new DHP derivatives were screened and the mostly active were selected for detailed studies. The compounds of the series of the amino acid ("free" plus "crypto")-containing DHPs and lipophilic di-cyclic DHPs demonstrated long-lasting neuroprotective and/or memory-enhancing action, particularly at low doses (0.005-0.05mg/kg) in different neurodeficiency rat or mice models, and exerted neurot…

0301 basic medicineGenetically modified mouseDihydropyridinesDHPSNeurotransmissionBiologyPharmacologyNeuroprotection03 medical and health sciences0302 clinical medicineMemoryAnimalsHumansPharmacologychemistry.chemical_classificationNeurotransmitter AgentsCalcium channelCalcium Channel BlockersNeuroprotectionAmino acid030104 developmental biologychemistrySynaptic plasticityNervous System DiseasesNeurotransmitter AgentsNeuroscience030217 neurology & neurosurgeryPharmacological Research
researchProduct

Expression of endogenous mouse APP modulates β-amyloid deposition in hAPP-transgenic mice

2017

Amyloid-β (Aβ) deposition is one of the hallmarks of the amyloid hypothesis in Alzheimer’s disease (AD). Mouse models using APP-transgene overexpression to generate amyloid plaques have shown to model only certain parts of the disease. The extent to which the data from mice can be transferred to man remains controversial. Several studies have shown convincing treatment results in reducing Aβ and enhancing cognition in mice but failed totally in human. One model-dependent factor has so far been almost completely neglected: the endogenous expression of mouse APP and its effects on the transgenic models and the readout for therapeutic approaches. Here, we report that hAPP-transgenic models of …

0301 basic medicineGenetically modified mouseMaleMurine amyloid-betaBACE1-ASMice TransgenicPlaque Amyloidlcsh:RC346-429Pathology and Forensic Medicine03 medical and health sciencesCellular and Molecular NeuroscienceAmyloid beta-Protein Precursor0302 clinical medicineMeningesAmyloid precursor proteinMedicineAnimalsHumansTransgenic miceSenile plaqueslcsh:Neurology. Diseases of the nervous systemNeuronsAmyloid beta-Peptidesbiologybusiness.industryAmyloidosisResearchP3 peptideBrainAmyloidosismedicine.diseasePeptide FragmentsBiochemistry of Alzheimer's diseaseAstrogliosisCell biologyMice Inbred C57BL030104 developmental biologyCaspasesAmyloid precursor proteinMutationbiology.proteinAbetaFemaleNeurology (clinical)businessNeuroscienceAlzheimer’s disease030217 neurology & neurosurgery
researchProduct

BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19.

2021

BNT162b2 is a highly efficacious mRNA vaccine approved to prevent COVID-19. This brief report describes the immunogenicity and anti-viral protective effect of BNT162b2 in hACE2 transgenic mice. Prime-boost immunization with BNT162b2 elicited high titers in neutralizing antibodies against SARS-CoV-2, which correlated with viral clearance and alleviated lung lesions in these mice after viral challenge.

0301 basic medicineGenetically modified mouseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)TransgenevirusesImmunologyefficacylcsh:Medicineimmunogenicitychallenge study03 medical and health sciences0302 clinical medicineDrug DiscoveryMedicinePharmacology (medical)030212 general & internal medicinePharmacologyMessenger RNAbiologybusiness.industrySARS-CoV-2Brief ReportImmunogenicitylcsh:RCOVID-19VirologyTiter030104 developmental biologyInfectious DiseasesmRNA vaccineImmunizationbiology.proteinAntibodybusinessVaccines
researchProduct